A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Glucodynamic Effects of LY3374849 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 18 Oct 2019
Price : $35 *
At a glance
- Drugs LY 3374849 (Primary) ; LY 3374849 (Primary) ; Insulin degludec; Insulin degludec
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 16 Oct 2019 Status changed from active, no longer recruiting to completed.
- 03 Oct 2019 Planned End Date changed from 18 Sep 2019 to 30 Sep 2019.
- 03 Oct 2019 Planned primary completion date changed from 18 Sep 2019 to 30 Sep 2019.